Sanofi (NASDAQ:SNY) Hits New 1-Year Low - Here's Why

Key Points

• Sanofi's stock reached a new 52-week low of $44.62 during trading and currently trades at $45.88.
• Despite recent declines, several analysts upgraded Sanofi's rating, with a consensus price target of $62.67 and an average rating of "Buy."
• The company reported $11.34 billion in revenue for the last quarter, exceeding estimates, although earnings per share fell short of projections.

Sanofi (NASDAQ:SNY - Get Free Report) reached a new 52-week low during trading on Tuesday . The company traded as low as $44.62 and last traded at $45.88, with a volume of 1139660 shares trading hands. The stock had previously closed at $45.65.

Analyst Ratings Changes

SNY has been the topic of several analyst reports. Barclays restated an "overweight" rating on shares of Sanofi in a research report on Wednesday, July 2nd. Deutsche Bank Aktiengesellschaft raised Sanofi from a "hold" rating to a "buy" rating in a research report on Tuesday, September 2nd. Morgan Stanley upgraded shares of Sanofi from an "equal weight" rating to an "overweight" rating and boosted their price target for the company from $56.00 to $58.00 in a research report on Monday, September 8th. JPMorgan Chase & Co. upgraded shares of Sanofi from a "neutral" rating to an "overweight" rating in a research report on Friday, August 8th. Finally, Wall Street Zen raised shares of Sanofi from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $62.67.

Sanofi Stock Up 0.1%

The stock's 50 day moving average price is $48.22 and its 200-day moving average price is $50.23. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.94 and a current ratio of 1.27. The company has a market cap of $112.16 billion, a PE ratio of 10.98, a PEG ratio of 1.07 and a beta of 0.51.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its earnings results on Thursday, July 31st. The company reported $0.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.96 by ($0.06). The business had revenue of $11.34 billion for the quarter, compared to the consensus estimate of $9.91 billion. Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The business's quarterly revenue was down 7.0% compared to the same quarter last year. During the same quarter last year, the firm posted $1.73 earnings per share. On average, analysts predict that Sanofi will post 4.36 earnings per share for the current year.

Institutional Trading of Sanofi

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Accent Capital Management LLC purchased a new stake in shares of Sanofi during the 1st quarter worth approximately $29,000. Eastern Bank grew its holdings in shares of Sanofi by 121.0% during the first quarter. Eastern Bank now owns 548 shares of the company's stock valued at $30,000 after purchasing an additional 300 shares during the last quarter. Ameritas Advisory Services LLC acquired a new stake in Sanofi in the second quarter worth about $28,000. Golden State Wealth Management LLC boosted its position in shares of Sanofi by 619.3% during the 1st quarter. Golden State Wealth Management LLC now owns 633 shares of the company's stock valued at $35,000 after purchasing an additional 545 shares in the last quarter. Finally, Banque Transatlantique SA acquired a new position in Sanofi during the first quarter valued at $33,000. Institutional investors and hedge funds own 14.04% of the company's stock.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.